 BOSTON, Jan. 05, 2022 GLOBE NEWSWIRE -- Imara Inc. Nasdaq: IMRA, a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 1013, 2022. 